Hosted by Dailymotion. For legal issues report at the Copyright Center, report us on DMC, or use the Instant Removal tool.
J&J Lifts Forecast
Description
Johnson & Johnson beat Q1 estimates with adjusted EPS of $2.70 and revenue of $24.1B, up nearly 10% year over year. Cancer drug Darzalex generated $4B and psoriasis treatment Tremfya brought in $1.6B, both topping estimates. Autoimmune drug Stelara fell ~60% to $656M amid biosimilar competition. J&J raised its 2026 revenue forecast to $100.8B and EPS outlook to $11.55.
More from User
00:55
Apple Hikes Incoming
Benzinga
00:58
Trump Settles Niece Lawsuit
Benzinga
00:58
House Eyes Airline Rules
Benzinga
00:57
Intel-Apple Deal
Benzinga
00:50
Senate Targets Buybacks
Benzinga
00:58
CarMax Stock Sinks
Benzinga
Related Videos
00:35
Global Oncology Biosimilars Market is all set to grow exponentially
Yvar Everts
00:30
DDB Healthcare pour France Psoriasis - lutte contre le psoriasis, "Pour un regard plus doux sur le psoriasis" - octobre 2013
Stratégies Créations
00:46
Oncology Biosimilar Market: Trends, Insights & Future Growth 2024
Mukesh idalgave
00:39
Lifts Acacia Ridge Aussie Lifts QLD
sensis02
01:05
Car Lifts, Motorcycle Lift, Car Storage Lift Equipment- Indy Auto Lift LLC
netbizvideos
05:43
Lantern Pharma is Using Artificial Intelligence to Develop Oncology Treatments
CW7 Arizona